Regeneron said on Monday its experimental drug helped patients preserve up to 51% of lean mass and lose more fat when used in combination with Novo Nordisk's popular obesity drug Wegovy in a mid-stage ...

Some new medications in development are also trying to solve for a persistent side effect of existing drugs: Patients who ...

Overweight patients given an experimental weight loss drug being developed by China's Sciwind Biosciences lost an average of ...

Regeneron licensed a weight loss drug and revealed study data for a pair of muscle-preserving medicines. Elsewhere, two neuroscience biotechs cut deals and Bluebird officially went private.

Regeneron Pharmaceuticals has announced that it will be gaining rights to Hansoh Pharmaceuticals’ investigational dual GLP-1/GIP receptor agonist in a deal worth $2bn. The in-licensing agreement will ...

GLP-1 drugs like Ozempic help with weight loss, but how do they stack up against bariatric surgery? A new study breaks it ...

In combination with Eli Lilly’s tirzepatide, marketed as Zepbound for obesity, Scholar Rock’s monolonal antibody helped ...

A Phase 3 trial in obesity in China and a Phase 2b study in ... across Regeneron’s broad pipeline of obesity and metabolic programs focused on improved quality of weight loss, co-morbidities ...

Regeneron Pharmaceuticals has signed a new licensing agreement with Hansoh Pharmaceuticals Group to develop and sell its weight loss therapy ... by the Food and Drug Administration, which is ...

Blockbuster weight-loss drugs from Novo Nordisk ... shed about 23 pounds in the study, about 7.9 pounds of which constituted lean mass, while the combination of Regeneron's trevogrumab and Wegovy ...

In the 599-patient study, those on Wegovy alone lost ... as they vie for a share of the potential $150 billion weight-loss drug market. Regeneron also said it will license an experimental obesity ...